Valo Therapeutics, the Finnish developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases, and biotech ImmunoScape have identified immunogenic peptides for the development of a pan coronavirus vaccine.
ImmunoScape has an immunomics-based technology platform that provides unprecedented insights into the human immune system.
ImmunoScape’s Deep Immunomics platform enables the characterisation of a patient’s immunome at ultra-high resolution.
This technology shows the immune system in action by directly observing the modulation of phenotype, function, and specificity of individual immune cells, at scale and over time.
The analysis has been performed directly on blood cells from COVID-19 convalescent patients with different clinical outcomes and has allowed the identification of specific CD8+ T-cell responses relevant to Sars-CoV-2.
In follow up, Valo Tx, will use its proprietary PeptiVAX technology to coat a spike-expressing adenoviral vector vaccine with HLA-restricted peptides identified by Valo working with the University of Helsinki ImmunoViroTherapy Lab (IVTLab), led by Professor Vincenzo Cerullo. The study indicated that these peptides may be associated with a clinically beneficial T cell immune responses to Sars-CoV-2’s highly conserved genes.
When these peptides are applied to adenovectors using PeptiVAX, they are expected to generate strong T-cell responses against the selected antigens.
The research focuses on peptide sequences related to conserved antigens across the Coronavirus family with the aim to develop a pan coronavirus vaccine that will also deliver protection against emerging Sars-CoV-2 variants.
Three of the COVID-19 vaccines currently approved by regulators for many geographies across the globe utilise an adenovirus vector encoding spike protein and have demonstrated clinical safety and efficacy.
Through the collaboration between Valo Tx and ImmunoScape, it has been possible to identify conserved peptide sequences that will be applied to adenoviruses to address the efficacy issues of current vaccines against new COVID-19 variants.
The PeptiVAX platform provides a more flexible and faster approach to addressing new variants by coating the adenovirus with the associated clinical grade target peptides rather than re-engineering and manufacturing a completely new viral vector.
Paul Higham, CEO of Valo Tx, said: “Our PeptiVAX technology is rapidly adaptable to the emergence of new strains or even an entirely new coronavirus.
“By leveraging our innovative PeptiVAX technology platform with partners to identify novel peptides from conserved proteins, beyond the currently identified spike proteins, our goal is to create a new vaccine that will not only protect against the current COVID-19 variants, but also provide optimal resilience against potential future Ccoronavirus pandemics.”
Choon-Peng Ng, CEO at ImmunoScape, said: “The future of immunotherapy development depends upon an enhanced ability to observe and analyse the complex immune responses at high resolution. At ImmunoScape, we focus on illuminating the immune landscape.
“Our collaboration with Valo Tx gives us a powerful spotlight to find innovative ways to protect people from COVID-19 variants that may be resistant to current vaccines.”